Liposomal cyclosporin pharmaceutical formulation
    1.
    发明授权
    Liposomal cyclosporin pharmaceutical formulation 失效
    脂质体环孢菌素药物制剂

    公开(公告)号:US5683714A

    公开(公告)日:1997-11-04

    申请号:US417487

    申请日:1995-04-05

    IPC分类号: A61K38/13 A61K9/127

    CPC分类号: B82Y5/00 A61K38/13

    摘要: An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, phosphatidylglycerol and a cyclosporin in a mole ratio of from 25:3:1 to 17:3:1 is described. The formulation includes unilamellar vesicles having reduced toxicity. The formulation is used as an immunosuppressive agent and is an enhancer of the efficacy of antineoplasties for drug resistant cancer cells. A method is also provided for inhibiting the growth of cancer cells.

    摘要翻译: 描述了一种改进的脂质体环孢菌素治疗制剂,其包含摩尔比为25:3:1至17:3:1的磷脂酰胆碱,磷脂酰甘油和环孢菌素。 该制剂包括具有降低的毒性的单层囊泡。 该制剂用作免疫抑制剂,并且是用于抗药性癌细胞的抗肿瘤功效的增强剂。 还提供了抑制癌细胞生长的方法。

    Pharmaceutical formulation and process
    3.
    发明授权
    Pharmaceutical formulation and process 失效
    药物配方和工艺

    公开(公告)号:US5688525A

    公开(公告)日:1997-11-18

    申请号:US85673

    申请日:1993-06-30

    摘要: A process for preparing a liposomal cyclosporin therapeutic formulation, which comprises dissolving a combination of a neutral and negatively charged phospholipid and a cyclosporin in an organic solvent; drying the solution to form a solid phase, and hydrating the solid phase in an aqueous solution having a pH ranging from 7.5 to 9.5.

    摘要翻译: 一种制备脂质体环孢菌素治疗制剂的方法,其包括将中性和带负电荷的磷脂和环孢菌素的组合溶解在有机溶剂中; 干燥溶液以形成固相,并将固相在pH为7.5至9.5的水溶液中水合。